Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Copka Sonpashan

ClinicalTrials.gov lists Copka Sonpashan as lead sponsor of 40 trials. It has 34 active development programs and 3 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 23 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Active development programs Active development programs 34 Approved assets Approved assets 3 Sponsor delivery record Sponsor delivery record 1 Latest dated events Latest dated events 40 Disease areas Disease areas 23 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Active development programs Active development programs 34 Approved assets Approved assets 3 Sponsor delivery record Sponsor delivery record 1 Latest dated events Latest dated events 40

Rows recorded per section (log scale)

18 sections measured, none recorded

This page covers Copka Sonpashan: 40 lead-sponsored trials and 0 legal-entity registrations.

Get the Copka Sonpashan report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (23)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Deglutition Disorders 12
Stroke 8
Parkinson Disease 4
Brain Injuries 2
Brain Injuries, Traumatic 2

Showing 5 of 23 disease areas.

Start your 14-day trial Email me all 23 disease areas as a PDF

Trials by start year as sponsor or collaborator (2)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2024 39
2022 1

Forecast of the full-year count, planned starts included, not rows of this table: about 0 trials starting in 2026 and about 0 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Recruitment duration, a model prediction: none of the 40 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Active development programs (34)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Lidocaine Deglutition Disorders Not reported 3
Systemic Therapy Cerebral Palsy Not reported 1
Active Breathing Exercises Deglutition Disorders Not reported 1
Active Breathing Exercises Stroke Not reported 1
Routine Therapy Autistic Disorder Not reported 1

Showing 5 of 34 active programs.

Start your 14-day trial Email me all 34 active programs as a PDF

Approved assets (3)

Shown in this order: max phase first.

Approved assets
Drug Trials
Lidocaine 10
0,9% Chloride Sodium 2
BOTULINUM TOXIN TYPE-A 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
0 of 1 hit target (n=1) 1 of 1 on time (n=1)

Latest dated events (40)

Shown in this order: newest first.

Latest dated events
Date Event Source
2024-05 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-05 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 40 events.

Start your 14-day trial Email me all 40 events as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, journals published in, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.